AD Pipeline Update: LEO Pharma Reports Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe AD May 12, 2025
AD Pipeline Watch: First Patient Dosed in Phase 2b Clinical Trial Program of Zabalafin Hydrogel April 8, 2025
Shared-decision Making in AD: Incorporating the Minimal Disease Activity Concept With Vimal Hasmukh Prajapati, MD, FRCPC April 7, 2025
